



S I N G U L A R  
G E N O M I C S

## **Singular Genomics Systems, Inc. to Report First Quarter 2022 Financial Results on May 10, 2022**

April 26, 2022

LA JOLLA, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2022 after the market close on Tuesday, May 10, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at [investor.singulargenomics.com](http://investor.singulargenomics.com), in the Presentations & Events section.

### **About Singular Genomics Systems, Inc.**

Singular Genomics is a life science technology company that is leveraging novel NGS and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products as well as our core product tenets: power, speed, flexibility, and accuracy. We are currently developing two products that are purpose-built to target applications in which these core product tenets matter most. Our first product, the G4, targets the NGS market. Our second product in development, the PX, combines single-cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to offer a versatile multiomics solution.

### **Investor Contact**

Matt Clawson  
949-370-8500  
[ir@singulargenomics.com](mailto:ir@singulargenomics.com)

### **Media Contact**

Dan Budwick, 1AB  
973-271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)